VTRO (Vitro Biopharma) ROCE %: -338.60% (As of Oct. 2022)

What is Vitro Biopharma ROCE %?

Vitro Biopharma VTRO ROCE % is -338.60% as of Oct. 2022. The stock has 6 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Vitro Biopharma's annualized ROCE % for the quarter that ended in Oct. 2022 was -338.60%.

Vitro Biopharma (AMEX:VTRO) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Vitro Biopharma ROCE % Related Terms

Vitro Biopharma ROCE % Historical Data

* Premium members only.

The historical data trend for Vitro Biopharma's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vitro Biopharma ROCE % Chart

Vitro Biopharma Annual Data

Trend

Oct09

Oct10

Oct11

Oct12

Oct13

Oct14

Oct15

Oct17

Oct21

Oct22

ROCE %

Get a 7-Day Free Trial

0.00

-83.62

-84.65

Vitro Biopharma Quarterly Data
	Oct00	Oct01	Oct02	Oct03	Oct04	Oct05	Oct06	Oct07	Oct08	Oct09	Oct10	Oct11	Oct12	Oct13	Oct14	Oct15	Oct17	Oct21	Oct22
ROCE %	Get a 7-Day Free Trial														0.00	0.00	0.00	-334.48	-338.60

Vitro Biopharma ROCE % Calculation

Vitro Biopharma's annualized ROCE % for the fiscal year that ended in Oct. 2022 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Oct. 2022 )		(A: Oct. 2021 )		(A: Oct. 2022 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Oct. 2022 )		(A: Oct. 2021 )		(A: Oct. 2022 )
	=	-6.662	/	( ( (11.129 - 1.423)	+	(8.574 - 2.54) )	/ 2 )
	=	-6.662	/	( (9.706	+	6.034)	/ 2 )
	=	-6.662	/	7.87
	=	-84.65 %

Vitro Biopharma's ROCE % of for the quarter that ended in Oct. 2022 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Oct. 2022 )		(Q: Oct. 2021 )		(Q: Oct. 2022 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Oct. 2022 )		(Q: Oct. 2021 )		(Q: Oct. 2022 )
	=	-26.648	/	( ( (11.129 - 1.423)	+	(8.574 - 2.54) )	/ 2 )
	=	-26.648	/	( ( 9.706	+	6.034 )	/ 2 )
	=	-26.648	/	7.87
	=	-338.60 %

(1) Note: The EBIT data used here is four times the quarterly (Oct. 2022) EBIT data.

Frequently Asked Questions Learn more about ROCE % →

What does a ROCE % of -338.60% mean?

Vitro Biopharma (VTRO) has a ROCE % of -338.60% as of Oct. 2022.

Is Vitro Biopharma's ROCE % too high?

Vitro Biopharma's current ROCE % is -338.60%.

How does Vitro Biopharma's ROCE % compare to ?

Vitro Biopharma's ROCE % of -338.60% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good ROCE % for a Biotechnology company?

A good ROCE % depends on the Biotechnology industry context. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high ROCE % mean?

A high ROCE % can signal that a stock is expensive relative to its fundamentals. Vitro Biopharma's current ROCE % is -338.60%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Vitro Biopharma stock overvalued right now?

Vitro Biopharma (VTRO) has a current ROCE % of -338.60%. The current ROCE % is -338.60%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is ROCE % calculated?

ROCE % is calculated from a company's financial statements. For Vitro Biopharma (VTRO), the current ROCE % is -338.60% as of Oct. 2022. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Vitro Biopharma Business Description

Industry Healthcare Biotechnology

Comparable Companies

Address 4621 Technology Drive, Golden, CO, USA, 80403

Website http://www.vitrobiopharma.com

Vitro Diagnostics Inc is a US-based company, which is dedicated to providing high-quality commercialized cell lines, media, and stem cell technology for applications in stem cell research, drug discovery, and therapies. In addition, it also provides tools for clinical development focused on Mesenchymal Stem Cells (MSCs). Further, it offers cancer-associated fibroblasts (CAFs), which are used in the discovery of a new type of CAFs present in pancreatic cancer tumors, called pancreatic stellate cells. Geographically business activities are functioned through the region of United States.